Shantel
Key Takeaways:
- RoslinCT and Lykan Bioscience, two prominent Contract Development and Manufacturing Organizations (CDMOs) in the Cell and Gene Therapy industry, have announced their integration under the RoslinCT brand.
- The merger, facilitated by global investment firm GHO Capital, aims to create a dominant player in the Advanced Cell and Gene Therapy CDMO market.
- RoslinCT, with its rich heritage and expertise dating back to the cloning of Dolly the Sheep in 1997, brings a legacy of groundbreaking achievements and a strong focus on science and innovation.
- The combined organization, led by Peter Coleman in the UK and Patrick Lucy in the US, will offer comprehensive services, including process development, analytical testing, clinical and commercial cGMP manufacturing, and cGMP iPSC cell line development, gene editing, and differentiation.
- The state-of-the-art manufacturing facilities in Edinburgh, Scotland, and Boston, USA, will continue operations under the RoslinCT brand, with plans for further capacity expansion to meet the increasing global demand for Advanced Cell and Gene Therapy manufacturing services.
Integration of Two Leading Advanced Cell and Gene Therapy Organizations
RoslinCT and Lykan Bioscience, two renowned Contract Development and Manufacturing Organizations (CDMOs) in the Cell and Gene Therapy industry, have announced their integration. Facilitated by GHO Capital, a global investment firm, the merger aims to establish a dominant player in the Advanced Cell and Gene Therapy CDMO market. The unified business will operate under the RoslinCT brand.
RoslinCT: Rich Heritage and Focus on Science and Innovation
RoslinCT, with its roots tracing back to the historic cloning of Dolly the Sheep at the Roslin Institute in 1997, has a legacy of groundbreaking achievements. Established in 2006, RoslinCT was formed to apply cutting-edge science to the development of human medicines. The company has been at the forefront of producing clinical-grade human pluripotent stem cells and is currently working on the first CRISPR-edited stem cell-based therapy for a major disease pending marketing authorization.
Comprehensive Service Offerings and Global Capabilities
Under the leadership of Peter Coleman in the UK and Patrick Lucy in the US, the integrated organization will provide a comprehensive range of services. These include process development, analytical testing, clinical and commercial cGMP manufacturing, and cGMP iPSC cell line development, gene editing, and differentiation. By combining their resources and expertise, RoslinCT aims to empower Cell and Gene Therapy developers to advance their products through clinical trials and bring them to market.
Expansion of Manufacturing Facilities and Global Demand
The state-of-the-art manufacturing facilities located in Edinburgh, Scotland, and Boston, USA, will continue operations under the RoslinCT brand. There are plans for further capacity expansion on both sides of the Atlantic to meet the growing global demand for Advanced Cell and Gene Therapy manufacturing services.
For more information about the integrated organization and its services, please visit the new website at www.roslinct.com.
About RoslinCT
RoslinCT is a leading global Contract Development and Manufacturing Organization (CDMO) focused on Advanced Cell and Gene Therapies. Established in 2006, RoslinCT has harnessed cutting-edge science, including the cloning of Dolly the Sheep, to advance the development of human medicines. The company offers innovative process and analytical development, cGMP clinical and commercial manufacturing for various cell types, cGMP iPSC cell line development, gene editing, and differentiation.
